# Barrières bij implementatie van lipidenverlagende therapie in de praktijk

*geplaatst 2026-03-26 · Cholesterol · Circulation. Population health and outcomes · doi 10.1161/CIRCOUTCOMES.125.012330 · https://hartvaat.nl/2026/03/02/barrieres-bij-implementatie-van-lipidenverlagende-therapie-in-de-praktijk/*

Ondanks bewezen effectiviteit van lipidenverlagende therapieën blijft de implementatie in de dagelijkse praktijk suboptimaal. Dit artikel in Circulation analyseert de barrières — van therapietrouw tot financiële toegankelijkheid — en bespreekt strategieën om de kloof tussen richtlijnen en praktijk te dichten.

## English: 

Despite proven efficacy of lipid-lowering therapies, their implementation in daily clinical practice remains suboptimal. This Circulation article analyses barriers — from adherence to financial accessibility — and discusses strategies to close the gap between guidelines and practice.

## Abstract (original, from the publication)

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality globally. Low-density lipoprotein cholesterol is a causal risk factor for atherosclerotic cardiovascular disease, with multiple classes of cholesterol-lowering therapies effective at reducing atherosclerotic cardiovascular disease risk. Despite robust efficacy data from randomized trials, real-world implementation of guideline-recommended lipid-lowering therapies is suboptimal. Barriers to the implementation of guideline lipid-lowering therapy recommendations exist at the healthcare systems level, the medical therapy level, and the patient level. A combination of strategies, including the incorporation of quality improvement and cost-effectiveness analysis among payers, pharmacist-based educational initiatives, digital health tools directed towards patients, the simplification of drug regimens via polypill, and emerging novel therapies, including PCSK9 gene silencing and editing technologies, may bridge these implementation gaps. This review highlights challenges and solutions to alleviating barriers to optimal implementation of guideline-recommended lipid-lowering therapies.

Auteurs: Christopher S Marnell, Wolfgang Koenig, Vera Bittner, Karol E Watson, Paul Muntner, Børge G Nordestgaard, Lijing L Yan, Mariette Verbakel, Robert S Rosenson

---
Bron: Circulation. Population health and outcomes, https://doi.org/10.1161/CIRCOUTCOMES.125.012330. Bijgewerkt 2026-07-03T13:31:34Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.